Trial result ·
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.
Written based on 1 research study on PubMed, searched on 5 Nov 2026.
What was studied
This randomised trial ran at several centres. It tested ruxolitinib as the starting treatment for polycythemia vera. It was compared with other available therapy. 44 people got ruxolitinib and 34 got the other therapy. After 6 months, people on the other therapy could cross over to ruxolitinib. The main goal was a complete clinical and blood response at month 6.
What they found
The main goal was not met. Complete response rates were not higher with ruxolitinib. Ruxolitinib did better on blood thickness, spleen size, itching and tiredness. It did worse at lowering platelet counts. A gene marker, JAK2V617F, fell in both groups at 6 months. Time on treatment was longer with ruxolitinib over the 24-month study. No new safety signals appeared.
What it means for patients
The authors say ruxolitinib did not lead to higher complete response rates. They say it may bring clinically meaningful extra gains when used as the starting treatment.
Why it is not certain yet
The main goal was missed. The extra gains come from secondary and exploratory results. The abstract says only that such gains may occur. The trial had 44 and 34 people in the groups.
Source
Firstline treatment with ruxolitinib versus best available therapy in patients with polycythemia vera: results from the randomized RuxoBEAT trial.
PubMed · PMID 42918761We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Myeloproliferative neoplasms publications